GSK PLC GSK shares slid 2.47% to £14.43 Friday, on what proved to be an all-around dismal trading session for the stock ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE ... 2 Currently, there are no approved TKIs that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT.

When asked about the change in administration in the U.S., GSK CEO Emma Walmsley said, "Let's wait and see.” “There is categorically no better return on healthcare budgets and no better ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Tim Clackson, chief executive of IDRx, noted there had been 'no major advances to the standard of care for almost 20 years'. He added: 'Combining our experience to date with GSK's expertise in ...

The company, which was founded by industry veteran GSK Velu, has a track record of acquiring and integrating leading regional diagnostics players and scaling them under the Neuberg platform. Neuberg ...

and stressed that the settlements have been agreed "with no admission of liability." If pushed over the line, the settlements substantially resolve an issue that has been hanging over GSK for more ...